Summary:
- Merck, a leading pharmaceutical company, has announced plans to acquire Cidara Therapeutics, a biotechnology company focused on developing antiviral therapies.
- This acquisition will expand Merck's portfolio to include a late-phase antiviral agent, which could be used to treat various viral infections, including those caused by influenza and other respiratory viruses.
- The collaboration between Merck and Cidara Therapeutics aims to leverage their combined expertise in drug development and commercialization to bring new and innovative antiviral treatments to patients in need.